An HIV Vaccine: The World's best long-term hope for ending AIDS.

Who We Are

We are the world’s largest publicly-funded international collaboration focused on the development of vaccines to prevent HIV/AIDS. Learn more >

What We Do

Our sites conduct all phases of clinical trials - from evaluating experimental vaccines for safety and immunogenicity to testing vaccine efficacy. Learn more >

Get Involved

Worldwide, thousands of people have participated in HIV vaccine trials.  Volunteers are the heroes of vaccine development. Learn more >

HVTN Responds - No Justice, No Progress

HVTN RESPONDS – NO JUSTICE, NO PROGRESS

George Floyd, Gabriella Nevarez, Michelle Cusseaux, Alexia Christian, Breonna Taylor, Trayvon Martin, Michael Brown, Charlena Lyles, Stephon Clark, Terence Crutcher, Alton Sterling, Philando Castile, Che Taylor, Eric Garner, Mi’Chance Dunlap-Gittens, Laquan McDonald……the list of Black/African American people murdered continues to grow. This is unacceptable.

Epidemics and pandemics are magnifying glasses for tragedies. Those of us who have fought to address the biological outcomes of racial injustice work every day in communities where the human cry of “no justice, no peace” is resonating off the walls. It echoes with us as we try to work in a world where structural racism and discrimination consistently highlight difference.

Read the story >


file

HVTN participates in 23rd International AIDS Conference (virtual)

Join us in wishing Susan Buchbinder, M.D., Director of Bridge HIV at the San Francisco Department of Public Health and Stephaun E. Wallace, Ph.D., HVTN’s Director External Relations the best on their talks at the conference. Rafael Gonzalez, Community Programs Manager at Bridge HIV, San Francisco Department of Public Health will present a virtual poster presentation.

Read the statement >


Yunda Huang, Ph.D., flanked by her two children Yunda Huang

HVTN remains steadfast in the pursuit of a safe and globally effective preventive HIV vaccine

Yunda, a US citizen living in Shanghai, is a lead statistician on clinical trials coordinated by the HVTN. Similar to the HVTN study teams, Yunda found herself in a balancing act – to remain committed to the scientific journey for a safe preventive HIV vaccine while simultaneously supporting clinical trial sites’ response to COVID-19.

Read the story >


Novel Coronavirus SARS-CoV-2 NIAID - RML

Public statements by the HIV Vaccine Trials Network (HVTN) on COVID-19

April 1, 2020
The HVTN continues to monitor the impact of COVID-19 on the conduct of the early and large-scale clinical trials we coordinate globally.
Read the statement >


March 23, 2020
In consideration of COVID—19, we are taking measures to guard the safety and welfare of all study participants and study teams who help make all our clinical trials possible.
Read the statement >


Scholar Awards

We support the next generation of HIV researchers with structured mentoring, projects, training, and networking opportunities. Learn more >


Getting the Right Test for HIV

Getting the right test will prevent an incorrect diagnosis of HIV.  Your study site or VISP Testing Service can provide the right test.  Visit our frequently asked questions for more information.

TWITTER FEED


LATEST NEWS

HIV Vaccine Trials Network

Fred Hutchinson Cancer Research Center